Grifols SA (GIKLY) stock
GIKLYOTCPharmaceutical PreparationsAlso trades as GIFLF, GIFOF, GRFS
$5.55+0.00 (0.00%)
Close on Oct 19, 2026Market cap $1.91BP/E 4.2Yield –
Grifols r&d expenses
Research and development expenses are spending on new products and technology.
For fiscal 2025 it was €426.00M, up 10.9% from the year before. Over ten years it grew 6.6% a year on average. The highest annual figure on record is €426.00M in fiscal 2025.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | €426.00M | +10.9% |
| FY2024 | Dec 31, 2024 | €384.00M | -2.8% |
| FY2023 | Dec 31, 2023 | €395.00M | +9.4% |
| FY2022 | Dec 31, 2022 | €361.14M | +1.8% |
| FY2021 | Dec 31, 2021 | €354.88M | +20.6% |
| FY2020 | Dec 31, 2020 | €294.22M | +6.6% |
| FY2019 | Dec 31, 2019 | €276.02M | +14.7% |
| FY2018 | Dec 31, 2018 | €240.66M | -16.5% |
| FY2017 | Dec 31, 2017 | €288.32M | +45.9% |
| FY2016 | Dec 31, 2016 | €197.62M | -11.9% |
| FY2015 | Dec 31, 2015 | €224.19M | – |
See a number that looks wrong?